189 results on '"Baer, Alexandra"'
Search Results
2. Recurrent Valve Frame Infolding in the 34mm Self-Expanding Medtronic Evolut Pro+ Transcatheter Valve System: A Single Centre Experience
3. Cardiovascular Disease in Australians Experiencing Homelessness
4. Desmoplastic Small Round Cell Tumors: Clinical Presentation, Molecular Characterization, and Therapeutic Approach of Seven Patients.
5. Impact of CDK Inhibitors on TBXT Expression in Chordoma Cell Lines Including the First Stable Cell Line of a High-Grade Chordoma.
6. A systematic review of delayed high-grade atrioventricular block after transcatheter aortic valve implantation
7. Histomorphometric Analysis of 38 Giant Cell Tumors of Bone after Recurrence as Compared to Changes Following Denosumab Treatment
8. A Sketch-Based Interface for 2D Illustration of Vascular Structures, Diseases, and Treatment Options with Real-Time Blood Flow
9. Das 3D User Interface zSpace : Verwendung zur Exploration und Inspektion von Wirbeln der Halswirbelsäule
10. Statistical Analysis of a Qualitative Evaluation on Feature Lines
11. Characterization of Three Novel H3F3A-mutated Giant Cell Tumor Cell Lines and Targeting of Their Wee1 Pathway
12. Supplementary Figure 9 from Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway
13. Supplementary Figure 5 from Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway
14. Supplementary Table 5 from Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway
15. Supplementary Table 3 from Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway
16. Supplementary Table 4 from Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway
17. Supplementary Table 2 from Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway
18. Supplementary Figure 1 from Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway
19. Supplementary Figure Legend from Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway
20. Supplementary Figure 7 from Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway
21. Data Supplement from Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway
22. Supplementary Figure 2 from Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway
23. Supplementary Figure 8 from Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway
24. Supplementary Table 1 from Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway
25. Supplementary Figure 3 from Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway
26. Supplementary Figure 4A, B from Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway
27. Data from Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway
28. Supplementary Figure 4C from Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway
29. Supplementary Figure 6 from Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway
30. Prospective observational study on the accuracy of predictors of high-grade atrioventricular conduction block after transcatheter aortic valve implantation (CONDUCT-TAVI): study protocol, background and significance
31. Diagnostic value of MRI-based 3D texture analysis for tissue characterisation and discrimination of low-grade chondrosarcoma from enchondroma: a pilot study
32. Curvature- and Model-Based Hatching of Patient-Specific Muscle Surfaces
33. Curvature- and Model-Based Surface Hatching of Anatomical Structures Derived from Clinical Volume Datasets
34. Hardware-Accelerated Illustrative Medical Surface Visualization with Extended Shading Maps
35. Hardwaregestütztes Stippling von medizinischen Oberflächenmodellen
36. In chordoma, metastasis, recurrences, Ki-67 index, and a matrix-poor phenotype are associated with patients’ shorter overall survival
37. Epigenetic lockdown of CDKN1A (p21) and CDKN2A (p16) characterises the neoplastic spindle cell component of giant cell tumours of bone
38. Inhibition of phosphodiesterase‐4 promotes oligodendrocyte precursor cell differentiation and enhances CNS remyelination
39. Efficient Expression from One CMV Enhancer Controlling Two Core Promoters
40. Integrated FDG-PET-CT: its role in the assessment of bone and soft tissue tumors
41. Single-Batch Production of Recombinant Human Polyclonal Antibodies
42. H3F3A ‐mutated giant cell tumour of bone without giant cells—clinical presentation, radiology and histology of three cases
43. Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation
44. Metachronous and multiple aneurysmal bone cysts: a rare variant of primary aneurysmal bone cysts
45. Cystic Lesions With Suspected Soft Tissue Infiltration
46. Der Riesenzelltumor des Knochens – neue Aspekte, neue Probleme
47. Transcriptional properties of genomic transgene integration sites marked by electroporation or retroviral infection
48. Design und Realisierung eines Softwareassistenten zur Planung von Halsoperationen
49. Myelin-mediated inhibition of oligodendrocyte precursor differentiation can be overcome by pharmacological modulation of Fyn-RhoA and protein kinase C signalling
50. Architecture and utilization of highly expressed genomic sites
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.